Key takeaways
Oral semaglutide and injectable semaglutide contain the same active ingredient but differ in their form, dosage, and administration.
The best choice between oral semaglutide vs. injection depends on your goals, lifestyle, comfort, and health goals
In separate studies, injectable Wegovy has produced slightly greater average weight loss than oral Wegovy, but the results can’t be directly compared because the formulations were studied in different trials
Oral semaglutide may be preferred by those looking to avoid needles, while injectable semaglutide offers the convenience of once-weekly dosing.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Oral semaglutide and injectable semaglutide contain the same active ingredient but differ in their form, dosage, and administration.
The best choice between oral semaglutide vs. injection depends on your goals, lifestyle, comfort, and health goals
In separate studies, injectable Wegovy has produced slightly greater average weight loss than oral Wegovy, but the results can’t be directly compared because the formulations were studied in different trials
Oral semaglutide may be preferred by those looking to avoid needles, while injectable semaglutide offers the convenience of once-weekly dosing.
Semaglutide comes in two forms: oral tablets (Wegovy pill, Rybelsus, or the Ozempic pill) and injections (Ozempic, Wegovy). Other than the obvious difference (their forms), the key distinction is that you take oral tablets daily and inject the shots weekly.
Note: As of May 2026, Rybelsus is being phased out in favor of the Ozempic pill. This article uses “Rybelsus” for the remaining 3 mg, 7 mg, and 14 mg tablets; Ozempic tablets are available in 1.5 mg, 4 mg, and 9 mg strengths. The two formulations are not interchangeable milligram for milligram.
Oral vs. injectable semaglutide: key differences
| Oral semaglutide | Injectable semaglutide |
Brand names | Rybelsus, Wegovy pill, Ozempic pill | Ozempic, Wegovy |
FDA-approved indications | Rybelsus, Ozempic pill: - Control blood sugar levels in adults with type 2 diabetes (T2D) - Reduce the risk of major cardiovascular events in adults with T2D who are at high cardiovascular risk Wegovy pill: - Weight loss in adults with obesity, or overweight plus at least one weight-related health condition - Reduce cardiovascular risk in adults with heart disease and obesity or overweight
| Ozempic: - Control blood sugar levels in adults with T2D - Reduce the risk of major cardiovascular events in adults with T2D and established heart disease - Reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Wegovy: - Weight loss in adults with obesity or overweight plus at least one weight-related health condition - Reduce cardiovascular risk in adults with heart disease and obesity or overweight - MASH (a type of fatty liver disease) |
Frequency | Daily | Weekly |
How it’s taken | In the morning with up to 4 oz of plain water; wait at least 30 minutes before eating, drinking, or taking other oral medications | Subcutaneous injection on the same day each week under the skin of the abdomen, thigh, or upper arm |
Dosing | Rybelsus formulation R1: 3 mg, 7 mg, 14 mg* Wegovy pill: 1.5 mg, 4 mg, 9 mg, 25 mg Ozempic pill: 1.5 mg, 4 mg and 9 mg | Ozempic: 0.25 mg, 0.5 mg, 1 mg, 2 mg Wegovy: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg |
Common side effects | Nausea, stomach pain, diarrhea, decreased appetite, vomiting, constipation | Ozempic: Nausea, diarrhea, vomiting, constipation, stomach pain Wegovy: Nausea, diarrhea, vomiting, constipation, stomach pain or upset, dizziness, headache, fatigue, heartburn, gas |
Cost (without insurance) | Wegovy pill: $149–$299 depending on dose (cash price) Ozempic pill: $149–$299 depending on dose (cash price) | Ozempic pen: $1,027.51 (list price) or $199-$499 (cash price) Wegovy: $1,349.02 (list price) or $199–$399 (cash price) |
*As of May 2026, Rybelsus (the R1 formulation; 3 mg, 7 mg, and 14 mg) is being phased out in the U.S. as Novo Nordisk transitions to Ozempic tablets, the newer R2 formulation available in 1.5 mg, 4 mg, and 9 mg strengths.
Oral vs. injectable semaglutide: how they work
Although they differ in method of administration, oral and injectable semaglutide work similarly since they have the same active ingredient.
Semaglutide medications work by mimicking GLP-1, a hormone naturally produced by the body. It targets GLP-1 receptors involved in appetite, digestion, and blood sugar control throughout the gastrointestinal tract, pancreas, and brain.
Specifically, semaglutide works by:
Slowing down digestion, leading to an earlier feeling of fullness
Regulating the release of insulin and glucagon after eating, to help keep blood sugar levels stable
Sending signals to the brain indicating fullness
Together, these effects help stabilize blood sugar levels and reduce appetite, making semaglutide an effective treatment for type 2 diabetes, obesity, and more.
When comparing oral semaglutide vs. injectable, it's worth noting their difference in bioavailability, i.e. how much of the medication enters the bloodstream.
Semaglutide tablets have a much lower bioavailability than injections, which is one reason they're taken daily instead of weekly.
Injectable vs. oral semaglutide: dosages
The doses for injectable semaglutide and oral semaglutide differ. Here’s the breakdown.
Dosages
Oral semaglutide is available in several dosage strengths, ranging from 1.5 mg to 25 mg depending on the brand-name medication.
The Wegovy pill comes in the following strengths: 1.5 mg, 4 mg, 9 mg, 25 mg. The recommended maintenance dosage of Wegovy tablets is 25 mg daily.
The Ozempic pill (which is replacing Rybelsus) comes in the following strengths: 1.5 mg, 4 mg, and 9 mg. The typical maintenance dose is 4 mg or 9 mg daily.
With either formulation, your healthcare provider may have you start at the lowest dosage strength. They will then slowly increase the dose (i.e. titrate up) every 30 days.
For example, a typical dosage titration schedule for oral semaglutide (Rybelsus, Wegovy pill) might look like this:
| Wegovy pill | Rybelsus formulation R1* | Ozempic |
Days 1–30 | 1.5 mg daily | 3 mg daily | 1.5 mg daily |
Days 31–60 | 4 mg daily | 7 mg daily | 4 mg daily |
Days 61-90 | 9 mg | Continue 7 mg, or increase to 14 mg if additional blood sugar control is needed | 4 mg daily, or 9 mg if additional blood sugar control is needed |
Day 91+ | 25 mg daily | 7 mg or 14 mg daily | 4 mg or 9 mg daily |
*As of May 2026, Rybelsus is being phased out and transitioning fully to the Ozempic pill. Inventory of Rybelsus formulation R1 doses (3 mg, 7 mg, 14 mg) will remain available until depleted.
Injectable semaglutide (Wegovy, Ozempic) has its own dosage strengths for each brand-name version:
Ozempic: 0.25 mg, 0.5 mg, 1 mg, 2 mg
Wegovy: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg (known as Wegovy HD)
As with oral semaglutide, healthcare providers typically prescribe a low starting dosage. They then increase it every four weeks or so until you find a dosage that works for you.
For example, a typical dosage titration schedule for injectable semaglutide might look like this:
| Ozempic | Wegovy |
Weeks 1–4 | 0.25 mg weekly | 0.25 mg weekly |
Weeks 5–8 | 0.5 mg weekly | 0.5 mg weekly |
Weeks 9–12 | 1 mg weekly | 1 mg weekly |
Weeks 13–16 | 1 mg or 2 mg weekly | 1.7 mg weekly |
Weeks 16–20 | 1 mg or 2 mg weekly | 1.7 mg weekly or 2.4 mg weekly |
Weeks 20+ | 1 mg or 2 mg weekly | 2.4 mg weekly |
Weeks 24+ | 1 mg or 2 mg weekly | 7.2 mg weekly after 4 weeks on 2.4mg (if there is a clinical indication for further weight loss) |
Administration
Oral semaglutide is taken once daily in the morning on an empty stomach. This is true for Rybelsus, Ozempic tablets, and Wegovy tablets..
Specifically, oral semaglutide should be:
Swallowed whole with a small amount of water (up to 4 ounces)
Followed by a wait of at least 30 minutes before eating, drinking, or taking other oral medications
Injectable semaglutide is administered weekly via subcutaneous injection — meaning it's injected under the skin into the fatty area of the abdomen, thigh, or upper arm.
Here’s what else you need to know:
You inject semaglutide every week, on the same day each week, at any time during that day (with or without food).
You should rotate injection sites weekly so that you’re not doing the injection in the exact same place every time.
If needed, you can change your semaglutide injection day, as long as it’s been at least two days since your last dose. It’s a good idea to check with your healthcare provider before changing your dosing day so they can help you make the change safely.
Which is more effective for weight loss: oral or injectable semaglutide?
Injectable and oral semaglutide have both been shown to lead to substantial weight loss in clinical trials. In separate studies, injectable Wegovy has produced slightly greater average weight loss in some analyses, but the results can’t be directly compared because the formulations were studied in different trials.
In 68 weeks (about a year and a half), people taking Wegovy lost nearly 15% of their body weight (~34 pounds).
In 64 weeks (about a year and three months), people taking oral semaglutide (Wegovy pill) lost 13.6% of their body weight (~31 pounds).
Which is more effective for blood sugar control: oral or injectable semaglutide?
Both oral and injectable semaglutide can lower blood sugar in people with type 2 diabetes.
Oral semaglutide (Rybelsus) reduces HbA1c levels by 1.2%–1.4% at week 26, depending on the dosage strength you’re taking.
Injectable semaglutide (Ozempic) reduces HbA1c levels by 1.4%–1.6% at week 30, again depending on the dosage strength.
Some research comparing results across studies has not found a significant difference in blood sugar control between oral and injectable semaglutide.
Oral vs. injectable semaglutide: side effects and risks
Semaglutide tablets and injections share many similar side effects, since they both contain semaglutide as the active ingredient.
The most common side effects of both oral and injectable semaglutide include
Abdominal pain
Diarrhea
Vomiting
Injectable semaglutide (Ozempic, Wegovy) may also cause reactions at the injection site, such as rash or irritation, though these are rare.
Both oral and injectable semaglutide carry similar risks, including:
Acute pancreatitis
Diabetic retinopathy complications (diabetes-related vision changes)
Hypoglycemia (low blood sugar), especially when used with insulin
Acute kidney injury related to dehydration and gallbladder problems
Severe gastrointestinal reactions
Allergic reactions
Pulmonary aspiration during general anesthesia or deep sedation
Additionally, Wegovy carries warnings for increased heart rate All forms of semaglutide carry a black box warning for thyroid tumors based on animal studies. It’s not known whether semaglutide causes these tumors in humans. Semaglutide should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC), a specific type of thyroid cancer, or those with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Will there be more oral semaglutide options soon?
Yes. As of January 6, 2026, the Wegovy pill is available in the US, and you can get it on Ro (if appropriate, of course).
Oral Wegovy was FDA approved in late December 2025.
In May 2025, Novo Nordisk, the maker of Rybelsus, Wegovy, and Ozempic, applied for FDA approval of an oral version of Wegovy after completing a 64-week OASIS 4 phase 3 trial. The trial found that 25 mg of oral Wegovy taken daily reduced body weight by 13.6% over 64 weeks (about a year and three months).
"Most of my [patients with diabetes] prefer Ozempic injection to the Rybelsus pill, both of which are semaglutide variants," says Jennifer Brown, MD, ABOM, ABFM, a dual board-certified physician in family medicine and obesity medicine. "It will be interesting to see if real-world patients prefer Wegovy injections over oral Wegovy."
Semaglutide pills vs. injectable: how much they cost
The cost of semaglutide pills and injectables varies based on your insurance coverage. If you’re using insurance to pay for your semaglutide, call them or your pharmacy to get a cost estimate.
Otherwise, here are the cash-pay prices for semaglutide pills and injectables.
Oral semaglutide (Ozempic) | Oral semaglutide (Wegovy) | Injectable semaglutide (Ozempic) | Injectable semaglutide (Wegovy) |
Ozempic pill: $149–$299 depending on dose (cash price) | Wegovy pill: $149–$299 depending on dose (cash price) | Ozempic pen: $1,027.51 (list price) or $199-$499 (cash price) | Wegovy: $1,349.02 (list price) or $199–$349 (cash price) |
How to choose between oral and injectable semaglutide: 5 factors
Choosing the best form of semaglutide for you — semaglutide pills vs. injection — depends on your medical situation, lifestyle, and personal preferences. Here are some of the key decision factors to consider:
1. Your weight loss goals. If weight loss is your main goal, both oral and injectable Wegovy are options. The amount of weight loss can vary by dose and from person to person. Wegovy injections may produce nearly 15% weight loss over a year and a half. Ozempic and Rybelsus can also cause weight loss, although they are FDA-approved for type 2 diabetes rather than weight management
2. Your comfort with injections. To take Ozempic or Wegovy, you’ll need to inject yourself once a week. Oral semaglutide can be a preferred option for people who have an aversion to injections, Dr. Brown says.
3. Your lifestyle and administration needs. People who travel often may prefer a shelf-stable treatment — oral semaglutide is taken daily and doesn't need to be refrigerated. If a strict morning routine isn't practical, injectable semaglutide, taken just once weekly, may be a better fit, though it does need to be refrigerated.
4. Other medical conditions. Both Ozempic and Wegovy are approved to reduce cardiovascular risk in certain patients, and Ozempic is also approved to slow kidney decline in adults with type 2 diabetes and chronic kidney disease. A healthcare provider can help determine the best option for coverage.
5. Your insurance coverage and budget. The list prices for oral and injectable semaglutide medications are as follows: $997.58 for Rybelsus, $997.58 for Ozempic, and $1,349.02 for Wegovy. The Wegovy pill has a cash price of $149–$299 per month depending on the dose on Ro. Similarly, Wegovy pens cost $199–$349 per month depending on dose when opting for self-pay (also on Ro). Novo Nordisk offers savings programs for certain brand-name medications, but they come with eligibility requirements.
Which option may be best for you: oral or injectable semaglutide?
Your healthcare provider can help you determine whether oral or injectable semaglutide may be a better fit for you, based on your personal health situation and goals.
Oral semaglutide may be better if:
You have needle phobia or don’t like injections
You don’t want to worry about storing or properly disposing of needles and pens
You like the routine of taking a daily pill
You have type 2 diabetes and prefer a daily pill over a weekly injection
Your health insurance offers better coverage for it
Injectable semaglutide may be better if:
You prefer the flexibility of only having to do an injection once a week, at any time of day.
You don’t want to wait 30 minutes every morning before eating, drinking, or taking other medication after your oral semaglutide dose.
You take other medications in the morning and don't want to work around the oral semaglutide timing requirements.
You have another health condition for which a specific injectable semaglutide product is approved, such as certain forms of MASH or chronic kidney disease with type 2 diabetes.
Bottom line
Here are the main differences and similarities between oral and injectable semaglutide to help keep them top-of-mind:
They work the same way. Both stimulate GLP-1 receptors to help control blood sugar, slow digestion, and reduce appetite.
They're taken differently. Oral semaglutide is a daily pill with strict timing rules; injectable semaglutide is a once-weekly shot with more flexibility.
Side effects are similar, though the injectable version can also cause reactions where the medication is injected.
The amount of weight loss and blood sugar improvement can vary depending on the specific product, dose, and individual response.
Frequently asked questions (FAQs)
Is oral semaglutide as good as the injectable?
Both oral and injectable Wegovy can lead to substantial weight loss, but they haven't been directly compared in the same clinical trial. When studied separately, oral semaglutide was slightly less effective than injectable semaglutide for weight loss: people who took 25 mg of oral semaglutide (Wegovy pill) daily lost nearly 14% of their body weight after 64 weeks. Meanwhile, people who took 2.4 mg of injectable semaglutide (Wegovy) weekly lost nearly 15% of their body weight after 68 weeks.
How does semaglutide help weight loss?
Semaglutide helps with weight loss by slowing down digestion, leading to an earlier feeling of fullness. It also reduces appetite by sending satiety (fullness) signals to the brain. Thanks to these effects, people may eat less and lose weight as a result.
How much weight can you lose on oral semaglutide?
In one clinical trial, people taking Wegovy 25 mg tablets lost an average of about 13.6% of their body weight after 64 weeks (about a year and three months).
How much weight can you lose on injectable semaglutide?
In a clinical trial, people taking Wegovy 2.4 mg injections lost an average of about 15% of their body weight after 68 weeks (about a year and a half).
A newer 7.2 mg dose of injectable Wegovy is also FDA-approved for some adults who need additional weight loss after taking 2.4 mg for at least four weeks. In adults with obesity, people taking 7.2 mg lost an average of 18.8% of their body weight, compared with 15.5% with 2.4 mg
What are the main differences between oral and injectable semaglutide?
Oral semaglutide is a daily pill, while injectable semaglutide is injected once a week. The amount of weight loss and blood sugar improvement can vary by product and dose. Oral semaglutide may be more appealing to people who prefer a daily pill and want to avoid injections
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
References
Adams, B. & Kansteiner, F. (2026). Novo Nordisk’s Rybelsus officially retired in US as ‘Ozempic pill’ takes branding center stage. Fierce Pharma. Retrieved from https://www.fiercepharma.com/marketing/novo-nordisks-rybelsus-brand-officially-retired-us-ozempic-pill-takes-branding-center
Bonora, B. M., Russo, G., Leonetti, F., et al. (2024). Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study. Journal of Endocrinological Investigation, 47(6), 1395–1403. doi: 10.1007/s40618-024-02309-2. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11142994/
Chubb, B., Gupta, P., Gupta, J., et al. (2021). Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis. Diabetes Therapy, 12(5), 1325–1339. doi: 10.1007/s13300-021-01034-w. Retrieved from https://link.springer.com/article/10.1007/s13300-021-01034-w
Kommu, S. & Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/
Novo Nordisk-a. (2025). Company announcement: Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management. Retrieved from https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472
Novo Nordisk-b. (2025). Press Release: FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity. Retrieved from https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915988
NovoCare-a. (2025). Find out the cost for Ozempic. Retrieved from https://www.novocare.com/diabetes/products/ozempic/explaining-list-price.html
NovoCare-b. (2025). Find out the cost for Rybelsus. Retrieved from https://www.novocare.com/diabetes/products/rybelsus/explaining-list-price.html
NovoCare-c. (2025). What is the list price for Wegovy and will it impact me?. Retrieved from https://www.novocare.com/obesity/products/wegovy/let-us-help/explaining-list-price.html
Ozempic. (2026). Ozempic® (semaglutide) Cost and Insurance Coverage. Retrieved from https://www.ozempic.com/savings-and-resources/save-on-ozempic.html
U.S. Food and Drug Administration (FDA-a). (2026). Highlights of Prescribing Information: Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf
U.S. Food and Drug Administration (FDb). (2026). Highlights of Prescribing Information: Rybelsus (semaglutide) tablets, for oral use; Ozempic (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf
U.S. Food and Drug Administration (FDA-c). (2026). Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use; Wegovy (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England Journal of Medicine, 393(11), 1077–1087. doi: 10.1056/NEJMoa2500969. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40934115/
Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. doi: 10.1056/nejmoa2032183. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2032183














